Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has confirmed in a preclinical study, that increased the growth of cortical neurons by 40% with statistical significance in one arm of the study. That was achieved with a sub hallucinogenic dose.
Moreau telling Proactive this first part was designed to provide information on the dose and duration of infusion needed to achieve maximal cortical neurite outgrowth as well as the underlying mechanism of the drug’s action. The next step will be to look at treatment time and should be completed at the end of October.